CLDI logo

CALIDI BIOTHERAPEUTICS INC

CLDINYSE AMERICAN
🏆 #5478 by market capEarnings Nov 17US Equity
$1.05▼ $0.14 (−13.22%)
Live
🔔
Track CLDI
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 13.2%
7d▼ 5.4%
14d▼ 12.5%
30d▼ 19.8%
ytd▼ 94.4%
1y▼ 95.7%
🏦Market Cap
$483,459
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$1.04 – $1.06
52-Week Range
$1.05 – $27.84
Volume
$2.00B
Avg Volume
$1.80B
Shares Outstanding
460,437
Next Earnings
Nov 18, 2026

Fundamentals Snapshot

Annual Revenue
$31,599
Last Q Revenue
$7,564
P/E Ratio
-0.0
P/S Ratio
0.0x
EPS (TTM)
$-12.34
Dividend Yield
0.00%
Dilution (1yr)
+317.2%

Why Investors Own CLDI

  • ✓High-growth profile — revenue up +5.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 79% gross margin and 25% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CLDI logo

CALIDI BIOTHERAPEUTICS INC

CLDI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-508.9%▼ −743.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$20M▼ −7.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$21M▲ +8.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
451K▲ +317.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3M▲ +$481K YoY
StockOtter · stockotter.space

About CALIDI BIOTHERAPEUTICS INC

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$1.10
▲ +5.0% Upside
High Target$1.32
Low Target$0.94
Based on 34 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

CALIDI BIOTHERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift CLDI price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

CALIDI BIOTHERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.